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Abstract
Background: Heterozygous mutations of SFTPC, the gene encoding surfactant protein C (SP-C), cause sporadic and
familial interstitial lung disease (ILD) in children and adults. The most frequent SFTPC mutation in ILD patients leads
to a threonine for isoleucine substitution at position 73 (I73T) of the SP-C preprotein (proSP-C), however little is
known about the cellular consequences of SP-CI73T expression.
Results: To address this, we stably expressed SP-CI73T in cultured MLE-12 alveolar epithelial cells. This resulted in
increased intracellular accumulation of proSP-C processing intermediates, which matched proSP-C species
recovered in bronchial lavage fluid from patients with this mutation. Exposure of SP-CI73T cells to drugs currently
used empirically in ILD therapy, cyclophosphamide, azathioprine, hydroxychloroquine or methylprednisolone,
enhanced expression of the chaperones HSP90, HSP70, calreticulin and calnexin. SP-CI73T mutants had decreased
intracellular phosphatidylcholine level (PC) and increased lyso-PC level without appreciable changes of other
phospholipids. Treatment with methylprednisolone or hydroxychloroquine partially restored these lipid alterations.
Furthermore, SP-CI73T cells secreted into the medium soluble factors that modulated surface expression of CCR2 or
CXCR1 receptors on CD4+ lymphocytes and neutrophils, suggesting a direct paracrine influence of SP-CI73T on
neighboring cells in the alveolar space.
Conclusion: We show that I73T mutation leads to impaired processing of proSP-C in alveolar type II cells, alters
their stress tolerance and surfactant lipid composition, and activates cells of the immune system. In addition, we
show that some of the mentioned cellular aspects behind the disease can be modulated by application of
pharmaceutical drugs commonly applied in the ILD therapy.
Background
Biophysically active pulmonary surfactant contains a
mixture of lipids and hydrophobic surfactant proteins B
(SP-B) and C (SP-C). A normal composition and home-
ostasis of pulmonary surfactant is critical for its surface-
tension-reducing properties and gas exchange in the
alveolar region of the lung. SP-C is synthesized exclu-
sively by alveolar type II cells (AECII) as a 21 kDa pre-
protein (proSP-C). ProSP-C is further processed to the
4.2 kDa mature protein through a sequence of proteoly-
tic cleavages before being secreted together with lipids
and other surfactant components to the alveolar surface
[1-4]. Surfactant secretion is accomplished by fusion of
lamellar bodies, AECII-specific organelles for surfactant
assembly and storage, with the plasma membrane [5].
SNARE proteins, in particular syntaxin 2 and SNAP-23,
are required for regulated surfactant secretion. Both
proteins are associated with the plasma membrane and
to some degree with lamellar bodies [6,7]. In parallel to
secretion, AECII reinternalize and recycle surfactant
components from the alveolar surface by means of
endocytosis via clathrin-dependent and clathrin-inde-
pendent pathways, which include routing to early endo-
somes and multivesicular bodies [5].
Interstitial lung disease (ILD) is a heterogeneous group
of diseases of known and unknown etiology [8-10].
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Several histological and clinical subtypes of ILD are
linked to the SP-C protein deficiency caused by muta-
tions of the corresponding SFTPC gene [3]. Many SP-C
mutations cluster within the preprotein’s BRICHOS
domain and lead to misfolding of the preprotein, aber-
rant trafficking and processing [11]. To date, all affected
individuals with BRICHOS domain mutations have been
heterozygous with no detectable mature SP-C in their
lungs, suggesting a dominant-negative effect of the
mutant allele (e.g. Δexon4, L188Q) [11,12]. Moreover, in
cell lines expressing BRICHOS domain mutations,
proSP-C forms perinuclear aggregates, consistent with
the cell’s inability to clear aggregated misfolded proteins
and a toxic gain-of-function [12,13]. Various pathologic
mechanisms for these mutations causing chronic accu-
mulation of misfolded proSP-C have been proposed,
such as induction of endoplasmic reticulum (ER) stress,
cytotoxicity, and caspase 3- and caspase 4-mediated
apoptosis [14-16]. These factors might contribute to
ILD through cell injury and death of AECII. In addition
to the BRICHOS domain mutations, a second class of
SFTPC mutations has emerged. A heterozygous mis-
sense mutation, leading to a substitution of threonine
for isoleucine at position 73 of the proSP-C, is the most
frequent SFTPC mutation [17,18]. There is a strong
variability in the phenotype of these patients, ranging
from asymptomatic to early fatal cases [19]. I73T SP-C
(SP-CI73T) is marked by mistrafficking of the preprotein
to the endosomal compartment and by preserved secre-
tion of both mature and aberrant proSP-C and proSP-B
forms and their intra-alveolar accumulation [17,20,21].
Yet, current knowledge on SP-CI73T lacks a precise
understanding of the proSP-C processing abnormalities,
concurrent cell stress response and cytotoxicity, as well
as perturbations of the surfactant composition and
secretion.
Current treatment of the genetic interstitial lung dis-
eases in children is unfortunately empirical. Corticoster-
oids are anti-inflammatory and stimulate surfactant
protein transcription [22,23]. Chloroquine and its less
toxic derivative hydroxychloroquine [24,25] are used
and believed to act on the lysosomal function, i.e.
reduce vesicle fusion, exocytosis and proteolytic degra-
dation [26,27] or stimulate lamellar body biogenesis
[28]. Thus, there is a need to define the cellular
mechanism of the currently applied treatments. Poten-
tial therapeutic targets are cell chaperones which assist
in normal protein folding and are part of the cytopro-
tective mechanism that keeps control over misfolded
proteins either by folding them correctly or by directing
them to the degradation pathway [29,30]. Δexon4
SFTPC mutation and proSP-CΔexon4 accumulation upre-
gulate the major ER chaperone BiP in an attempt to
maintain surfactant biosynthesis in the presence of ER
stress [14]. The regulation of other chaperones, like
HSP90, HSP70, calreticulin and calnexin, is unknown.
Even so, without pharmacological manipulation, such
cytoprotective mechanisms may not be sufficient to
maintain production of the bioactive surfactant with a
normal lipid/protein composition. In addition, AECII,
stressed by aberrantly processed proteins, might signal
to and activate the surrounding cells, particularly those
of immune system, which could contribute to the SP-C-
associated disease.
The goal of this study was to investigate the intracel-
lular disturbances and intercellular signaling of AECII
affected by SP-CI73T expression and the ability of the
pharmaceuticals commonly used in ILD therapy to
modulate some of the cellular mechanisms behind the
diseases. We demonstrate the impact of I73T mutation
on proSP-C processing, AECII stress tolerance, surfac-
tant lipid composition and activation of the cells of the
immune system. In addition, we investigate modulation
of the disease cellular mechanisms by pharmaceutical
drugs applied in the ILD therapy.
Results
MLE-12 cells process proSP-CI73T differently from proSP-
CWT and accumulate proSP-CI73T processing intermediates
SP-C is synthesized exclusively by AECII as a 21 kDa
proSP-C which is processed to the 4.2 kDa mature pro-
tein through a sequence of C-terminal and N-terminal
proteolytic cleavages [2,3]. To identify potential proces-
sing differences between proSP-CWT and proSP-CI73T,
MLE-12 cells were transfected with plasmid vectors,
allowing expression of fusion proteins of proSP-C with
either C-terminal (N1) or N-terminal (C1) EGFP tag or
N-terminal HA-tag. Stable expression of the N-termin-
ally HA-tagged proSP-CWT resulted in appearance of a
strong protein band at ~21 kDa and weak bands at 22
kDa, 17 kDa, and 14 kDa (Figure 1A, left). ProSP-CI73T
yielded the same four bands, however all at equal inten-
sity in relation to each other, indicating accumulation of
proSP-CI73T forms (Figure 1A, left). The postulated pro-
cessing products based on their size and the fact that
the N-terminal HA-tag was still present are depicted in
Figure 1B. Mature SP-C was never detectable because of
the loss of the protein tag due to the final processing
steps at the N-terminus.
Transient expression of N-terminal and C-terminal
EGFP fusion proteins with proSP-C were detectable 24
hours post transfection (Figure 1A, middle and right).
Again, the processing intermediates of the N-terminally
tagged fusion proteins differed between proSP-CWT and
proSP-CI73T, showing accumulation of all four proSP-
CI73T bands for the mutant protein (Figure 1A, middle). In
contrast, no differences in the band pattern between
proSP-CWT and proSP-CI73T were observed for processing
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intermediates containing the C-terminal EGFP-tag (Figure
1A, right). This suggests that there is no change in the
cleavage pattern regarding the truncation of proSP-C from
the C-terminus, being the first proSP-C cleavage step [2].
The lowest band (Figure 1A and 1B, #10) corresponded to
the EGFP-tag, which has a size of ~27 kDa.
In summary, the expression of SP-CI73T in MLE-12
cells resulted in the intracellular accumulation of
intermediate processing products. Such processing forms
are also found in the BAL fluid of patients with this
mutation [17,21,31] and may reflect alterations in folding,
trafficking and/or processing of proSP-CI73T. Based on
these initial experiments we considered this in vitro cel-
lular system to be an appropriate model to study the
effects of SFTPC mutations on cellular physiology and
stress responses.
Figure 1 Processing features of proSP-CWT or proSP-CI73T. (A) Immunoblotting of total cell lysates with tag-specific antibodies. Cell lysates
obtained from MLE-12 cells stably expressing fusion protein of proSP-C with an N-terminal HA-tag (left panel), transiently transfected cells
expressing fusion protein of proSP-C with an N-terminal EGFP (EGFP-C1, middle panel) or a C-terminal EGFP (EGFP-N1, right panel), present with
several bands corresponding to different proSP-C processing intermediates, in which the tag sequence is retained. (B) Based on the size of the
bands, the projected corresponding intermediate species of the fusion constructs are depicted. The cleavage sites are only estimates due to the
limited resolution of the technique. EGFP-C1 (band #5) and EGFP-N1 (band #9) are expressed as a full-length product of 48 kDa, HA-SP-C (band
#1) of size 22 kDa.
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ProSP-CI73T localizes to different intracellular
compartments than proSP-CWT
The intracellular localization of preprotein species, mon-
itored by immunofluorescence, differed between proSP-
CWT and proSP-CI73T fusion proteins in MLE-12 cells
stably expressing N-terminally HA-tagged SP-C. Again,
with this approach mature SP-C was not detected
because of the loss of the HA-tag due to the final pro-
cessing steps at the N-terminus with only proSP-C
intermediates observed. ProSP-CWT forms were found
in the lamellar body-like structures detectable as
LAMP3-positive vesicles in MLE-12 cells (Figure 2A).
On the other hand, the proSP-CI73T signal was less vesi-
cular with a stronger cytoplasmic background and a
pronounced signal at the cell border, but still partially
colocalized with the LAMP3 (Figure 2A). This indicates
that proSP-CI73T intermediates do traffic to some extent
to LAMP3-positive vesicles. None of the proSP-C forms,
WT or I73T, colocalized with the ER-specific protein
calnexin, suggesting that no proSP-C species were ER
retained (Figure 2B). Surfactant secretion is dependent
on the fusion of lamellar bodies with the plasma mem-
brane, which requires the activity of SNARE proteins,
such as syntaxin 2 and SNAP-23, both associated to
some degree with lamellar bodies [6,7]. While proSP-
CWT forms colocalized well with syntaxin 2, proSP-
CI73T did not (Figure 2C). In contrast, proSP-CI73T
intermediates were found partially in early endosomes
detected as EEA1-positive vesicles, while proSP-CWT
was almost not present in those compartments (Figure
2D), confirming earlier data [17]. Early endosomes
usually contain endocytosed material that is destined for
recycling or degradation [32]. This suggests that physio-
logical proSP-CWT forms are secreted via lamellar body
fusion with the plasma membrane, while some proSP-
CI73T forms might take a different route.
Figure 2 Intracellular localization of proSP-CWT and proSP-CI73T forms in stabile MLE-12 cells. Immunofluorescent analysis with an
antibody against (A) lamellar body/lysosomal protein LAMP3 (red) and (B) ER protein calnexin (red) show complete localization of proSP-CWT
(green) forms and partial localization of proSP-CI73T (green) inside of lamellar body like organelles, and no colocalization of WT or mutant forms
with calnexin indicating no ER retention. While proSP-CWT localized with (C) syntaxin 2, a protein found within lamellar bodies as surfactant
secretory vesicles, and proSP-CI73T only partially, (D) proSP-CI73T was detectable in a significant amount in EEA1-positive early endosomes. Nuclei
are stained with DAPI (blue). Scale bars - 10 μm.
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Expression of SP-CI73T increases susceptibility of MLE-12
cells to exogenous stress imposed by pharmacological
substances
In order to determine the impairment of cells that
express SP-CI73T, lactate dehydrogenase (LDH) release of
stably transfected cells was determined. Expression of
SP-CI73T led to an overall slightly increased LDH release,
suggesting some reduction in cell viability (Figure 3).
Upon exposure of stable MLE-12 to pharmacological
substances currently applied in ILD therapy, the cells
expressing SP-CI73T showed more pronounced increase
in LDH release than cells expressing SP-CWT. Azathiopr-
ine treatment resulted in the most pronounced LDH
release, while the effect of hydroxychloroquine, methyl-
prednisolone and cyclophosphamide was significantly
lower (Figure 3). This demonstrates that the expression
of proSP-CI73T is a stress factor that may increase cell
vulnerability and susceptibility to exogenous stress. In
addition, our data suggest that some substances used in
the ILD therapy are a potent (azathioprine) to moderate
(hydroxychloroquine) or milder (methylprednisolone and
cyclophosphamide) stress factor per se.
Modulation of chaperone level in cells expressing SP-CWT
and SP-CI73T by pharmacologic substances
After demonstrating that SP-CI73T expression increases
cell vulnerability to pharmacological stress stimuli, we
further aimed to investigate the underlying intracellular
mechanisms. Chaperone proteins are involved in the
folding of aberrantly processed proteins and produced
by cells as a part of a cytoprotective mechanism to cope
with increased intracellular stress and accumulation of
misfolded proteins [29,30]. We determined a fold
change in the protein level of the two heat shock pro-
teins, HSP90 and HSP70, and two ER-resident chaper-
ones, calreticulin and calnexin, in MLE-12 cells
expressing SP-CWT and SP-CI73T, before and after expo-
sure to the pharmacologic substances used in ILD ther-
apy: cyclophosphamide, azathioprine,
methylprednisolone or hydroxychloroquine (Figure 4A-
D, Table 1). The expression of HSP90 was increased sig-
nificantly by all four pharmacologic substances tested in
I73T cells compared to WT. Calreticulin was also
increased in I73T mutant after the treatment with
hydroxychloroquine and HSP70 expression increased
after treatment with cyclophosphamide compared to
WT cells. Treatment with any of the four substances
did not alter the expression of calnexin between SP-
CWT and SP-CI73T-expressing cells (Figure 4). Overall,
the exposure of SP-CI73T-expressing cells to selected
pharmacologic substances increased expression of some
chaperones compared to SP-CWT cells, being a mechan-
ism, which might enhance general cell folding capacity.
Pharmacological modulation of intracellular localization
of proSP-CWT and proSP-CI73T
Knowing that tested pharmacological substances enhance
chaperone expression in cells with SP-CI73T in comparison
Figure 3 Viability of MLE12 cells expressing SP-CWT or SP-CI73T before and after treatment with drugs used in therapy. MLE-12 cells
stably expressing SP-CWT or SP-CI73T were incubated 24 hours with 10 μM of cyclophosphamide (+Cyc), azathioprine (+Aza), methylprednisolone
(+Met), or hydroxychloroquine (+Hyd). LDH release, a sign of deceased cell fitness, of treated vs. untreated (-) cells is expressed as % of total
LDH. Only significant p-values are depicted.
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to those expressing SP-CWT and that proSP-CI73T forms
are mislocalized to early endosomal vesicles, we investi-
gated influence of two drugs used in ILD therapy, hydro-
xychloroquine and methylprednisolone, on proSP-CWT
and proSP-CI73T. We applied again syntaxin 2 and EEA1
as markers for correctly localized and mislocalized proSP-
C respectively [7], in a quantitative immunofluorescence
study in order to determine the percentage of proSP-C-
positive vesicles that colocalized with either of the two
protein markers. As shown in Figure 2, we observed high
level of colocalization of proSP-CWT forms with syntaxin 2
and of proSP-CI73T with EEA1 (Figure 5A and 5B). Expo-
sure to both pharmacological substances reduced the loca-
lization of proSP-CWT to syntaxin 2-positive vesicles and
moved it toward EEA1-positive vesicles. However, even
after the drug treatment the colocalization level of WT
with EEA1 remained significantly under the level detected
in non-treated I73T mutant (Figure 5B). Furthermore,
while hydroxychloroquine did not significantly improve
mislocalization defect of the proSP-CI73T forms, we
observed correctional effect of methylprednisolone on
localization of proSP-CI73T. Namely, methylprednisolone
increased localization of the proSP-CI73T forms to the syn-
taxin 2-positive (Figure 5A) vesicles and decreased their
colocalization with EEA1 (Figure 5B). Nevertheless, even
after the pharmacological treatment proSP-CI73T never
completely acquired WT localization features (Figure 5A
and 5B). Our data suggest the ability of the methylpredni-
solone drug to partially correct mislocalization defect of
proSP-CI73T.
Figure 4 Modulation of chaperone level in the cells expressing SP-CWT and SP-CI73T by pharmacologic substances. Shown is the fold
change in protein level of the chaperone proteins HSP90, HSP70, calreticulin and calnexin in MLE-12 cells expressing proSP-CWT and proSP-CI73T
before and after their exposure to the drugs commonly applied in ILD therapy: (A) hydroxychloroquine, (B) methylprednisolone, (C) azathioprine
and (D) cyclophosphamide. Only significant p-values are presented.
Table 1 Chaperone level in MLE-12 cells expressing
mutant SP-CI73T in response to drugs used in ILD
therapy.
HSP 90 Calreticulin HSP 70 Calnexin
Cyclophosphamide + 30% * + 13% * + 41% * + 16%
Azathioprine +36% * + 8% + 7% - 13%
Hydroxychloroquine + 81% * + 75% * + 18% + 6%
Methylprednisolone + 55% * + 26% * + 8% - 9%
Presented are the results of three independent experiments and expressed as
% changes of the protein amounts in SP-CI73T cells compared to SP-CWT
expressing cells; * denotes p-values < 0.05
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Alterations in the intracellular lipid composition and
composition of secreted lipids due to expression of SP-
CI73T and their response to pharmacological treatment
The packaging and secretion of lung surfactant lipids is
very closely linked to the expression of the hydrophobic
surfactant proteins in AECII [5]. Mass spectrometric
lipid analysis showed that total phospholipid amount
was not changed in transfected MLE-12 cells (Table 2).
However, the phospholipid composition was significantly
altered: phosphatidylcholine (PC) and sphingomyelin
were decreased and lyso-phosphatidylcholine (LPC) and
phosphatidylethanolamine were increased in I73T
mutant cells (Table 2, Figure 6). Treatment with methyl-
prednisolone or hydroxychloroquine did not correct the
loss of PC in SP-CI73T expressing cells, but it did ame-
liorate the LPC increase (Figure 6A). Also significant
changes in the pattern of the fatty acids molecular spe-
cies of different phospholipid classes were measured
(Table 2, Additional file 1: Supplemental Table S1), sug-
gesting that the lipid sorting processes of the cells were
also affected substantially.
The phospholipid secretion by MLE-12 cells was
assessed in the supernatant. Similar as in the intracellu-
lar lipid pattern, PC was decreased by 27% and LPC was
increased by 57% in cells expressing SP-CI73T (Figure
6B), with no changes detected for other phospholipids
(data not shown). Interestingly, the treatment with
methylprednisolone or hydroxychloroquine ameliorated
the reduction of PC, but had no effect on LPC. Our
data suggest that the expression of SP-CI73T affected the
lipid composition of AECII and alveolar pulmonary sur-
factant profoundly. The major surfactant phospholipid
PC was reduced with a concomitant increase in LPC,
suggesting increased activity of phospholipases. Treat-
ment with methylprednisolone or hydroxychloroquine
corrected to some extent these alterations back toward
the WT level.
MLE-12 cells expressing SP-CI73T secrete soluble factors
that stimulate surface expression of CCR2 and CXCR1 on
CD4+ lymphocytes and CXCR1 on neutrophils
Injury of the lung epithelial cell caused by endogenous
and exogenous stress may be communicated to the sur-
rounding immune cells, in particular to the pulmonary
Figure 5 Influence of methylprednisolone and hydroxychloroquine on intracellular localization of SP-CWT or SP-CI73T. Stabile MLE-12
cells expressing SP-CWT or SP-CI73T were incubated 24 hours with 10 μM of methylprednisolone (+Met) or hydroxychloroquine (+Hyd) and
analyzed by immunofluorescence followed by quantification of colocalization or proSP-C (HA-tag) with syntaxin 2 (marker of surfactant secretory
vesicles) and EEA1 (endosomal marker). Only significant p-values are shown.
Table 2 Phospholipid profile of transfected MLE-12 cells
stably expressing mutant SP-CI73T.
WT I73T P
(Anova)
Total phospholipids (nmol/mg
protein)
152.80 ±
9.6
153.10 ±
10.0
ns
Phospholipid classes (% of total
PL)
Phosphatidylcholine 57.80 ±
1.0
53.70 ± 0.8 < 0.001
Lyso-Phosphatidylcholine 0.60 ± 0.1 1.00 ± 0.8 < 0.001
Phosphatidylglycerol 0.30 ± 0.0 0.20 ± 0.1 ns
Sphingomyelin 6.20 ± 0.3 5.50 ± 0.2 < 0.05
Ceramide 1.80 ± 0.1 1.80 ± 0.1 ns
Glucosyl-Ceramide 0.10 ± 0.0 0.10 ± 0.0 ns
Phosphatidylethanolamine 11.20 ±
0.5
14.70 ± 0.8 < 0.001
Phosphatidylserine 6.50 ± 0.1 6.60 ± 0.3 ns
Data are means of three independent experiments each performed in
duplicate. P-values are given.
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leukocytes, leading to inflammation and cell remodeling.
Chemokine receptors recruit leukocytes to the alveolar
site of inflammation and orchestrate local immune
responses [33,34]. In the previous studies we demon-
strated that, among a plethora of chemokine receptors
involved in this network, specifically CCR2 on lympho-
cytes and CXCR1 on neutrophils, modulate pulmonary
immunity in human inflammatory lung diseases [35,36].
Therefore, we examined whether cells expressing SP-
CI73T stimulated the expression of CCR2 on lymphocytes
and CXCR1 on neutrophils by incubating isolated neu-
trophils or lymphocytes with 7-fold concentrated super-
natants of MLE-12 cells expressing WT or I73T SP-C. As
a result, CD8+ lymphocytes did not show a difference
between WT and I73T mutant, however CD4+ lympho-
cytes showed an increased level of surface receptor CCR2
expression in response to the supernatant of proSP-CI73T
expressing cells (Figure 7A). We observed the same pat-
tern with CXCR1, which was increased on CD4+ lym-
phocytes after incubation with the mutant cell
Figure 6 Intracellular lipid content and lipid secretion of MLE-12 cells expressing SP-CWT or SP-CI73T. (A) Intracellular lipid content of cells
stably expressing WT SP-C or I73T mutant were quantified by mass spectrometry. Untreated cells (-) or cells treated with 10 μM
methylprednisolone (+Met) or hydroxychloroquine (+Hyd) for 24 hours prior to sample isolation. Values were calculated as % of the mean of the
untreated WT values. (B) after removal of detached cells, the lipids in the cell supernatant were analysed and presented as in (A). The graphs
show relative amounts of phosphatidylcholine and lyso-phosphatidylcholine. Only significant p-values are depicted.
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supernatant, but was unaltered on CD8+ lymphocytes
(Figure 7B). We further analyzed the surface receptor
expression on neutrophils. The supernatant of SP-CI73T
expressing cells increased the level of CXCR1 expression
on neutrophils, but did not affect CD11b levels (Figure
7C). Non-concentrated supernatants gave the same
results, although less pronounced and a clear concentra-
tion dependency of the effects was observed (data not
shown). This suggests that SP-CI73T-expressing MLE-12
cells were able to modulate the surface receptor expres-
sion on the cells of immune system through the secretion
of soluble factors into the medium.
Discussion
Mutations in the SFTPC gene are a known cause of sur-
factant deficiency and very variable genetic ILD in chil-
dren and adults. We investigated the intracellular
disturbances and intercellular signaling of MLE-12 cells
expressing SP-CI73T and the ability of pharmaceutical
drugs used in ILD therapy to modulate some of the cel-
lular consequences of SP-C deficiency caused by this
mutation. MLE-12 cells were chosen as a model system
since they contain structures, which resemble lamellar
bodies seen in AECII [37]. The presence of lamellar
body-like structures in the cells used was confirmed by
electron microscopy (data not shown). Here we named
the organelles detectable as LAMP3-positive vesicles,
lamellar body-like structures.
A potential limitation of the study is that our system
corresponds rather to a homozygous than to a heterozy-
gous SFTPC mutation where one WT copy is still pre-
sent. Although endogenous SP-C is expressed in the
MLE-12 cells [38], expression of exogenous SP-C from
the CMV promoter present on the plasmid vector is
likely higher. However, all known patients with SP-C
mutations are heterozygous, expressing one copy of the
wild type gene. Thus, the experimental model reflects
the in vivo condition. In addition, in contrast to SP-
CΔexon4 or SP-CL188Q, I73T is a non-BRICHOS domain
mutation and does not lead to the conformational dis-
ease observed for BRICHOS domain mutations where
the mutant allele acts in a dominant-negative way [13].
Consequently, I73T still allows for the production of
mature SP-C in vivo [17].
Stable transfection of MLE-12 cells with SP-CWT or
SP-CI73T led to the intracellular accumulation of proSP-
CI73T processing intermediates which were not found in
cells with proSP-CWT, but corresponded well to species
in the BAL fluid of patients with this mutation [17] (Fig-
ure 1). The first step in proSP-C processing is a cleavage
at the C-terminal end [2]. Using an EGFP-tag fused to
the C-terminus of proSP-C showed no difference in pro-
cessing intermediates of proSP-CWT and proSP-CI73T
(Figure 1, right). This means that (a) the first cleavage
Figure 7 Surface receptor expression on human lymphocytes
and neutrophils. Neutrophils and lymphocytes were isolated from
the whole blood of different human donors and incubated with 7-
fold concentrated supernatants obtained from MLE-12 cells
expressing SP-CWT or SP-CI73T prior to flow cytometry analysis. Non-
concentrated supernatants gave the same results, although less
pronounced with a clear concentration dependency of the effects
(data not shown). The receptor levels on the surface of lymphocytes
after incubation with antibodies directed against (A) CCR2 or (B)
CXCR1 are shown and expressed as mean fluorescence intensity
(MFI). Another second marker-specific antibody was applied to
distinguish between CD4+ and CD8+ lymphocytes. (C) The levels of
CXCR1 and CD11b on isolated neutrophils. Significant changes are
depicted with the corresponding p-values.
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step happening at C-terminus is not influenced by this
mutation and (b) the mutation does not interfere with
the export from the ER and Golgi, because this cleavage
occurs after trafficking through these compartments
[2,3]. In addition, immunofluorescence assays showed
neither proSP-CWT nor proSP-CI73T retention in the ER
compartment (Figure 2), supporting the conclusions
made from the immunoblots. To examine the proces-
sing following the first C-terminal cleavage, we applied
N-terminal protein tags. Dominant proSP-CWT inter-
mediates, that were also identified for proSP-CI73T, were
the species after the first C-terminal cleavage (Figure 1,
bands #2 and #6), and the species before the first N-
terminal cleavage (Figure 1, band #8). The primary full-
length translation product (Figure 1, bands #1 and #5)
was only faintly detectable for proSP-CWT. Expression
of proSP-C in this model is under control of a CMV-
promoter, not the native SP-C promoter. It is therefore
unlikely that a feedback mechanism is responsible for a
higher expression of proSP-CI73T intermediates. It is
more likely that the I73T mutation slows down the pro-
cessing and/or trafficking of the mutant proSP-C, lead-
ing to accumulation of incompletely processed proSP-C.
It is not known how this mutation affects the folding of
proSP-C, but subtle changes in conformation may also
be responsible for the abundance of another processing
intermediate, of size ~17 kDa (Figure 1, band #3 and
#7). This intermediate can be found in the BAL fluid of
patients with the I73T mutation, suggesting that this
proSP-C form is being secreted from AECII along with
the mature SP-C that is produced by AECII regardless
of the presence of the I73T mutation [17].
Immunofluorescence assay of stably transfected MLE-
12 showed that proSP-CI73T colocalized often with
EEA1 positive vesicles (Figure 2A), confirming our pre-
vious report (12). Early endosomes generally contain
material that is taken up by endocytosis and is either
recycled or routed for degradation [32]. Up to 80% of
used lung surfactant is known to be reinternalized by
AECII from alveolar space [5]. Although immunofluor-
escence does not allow the distinction between different
EGFP-positive species depicted in Figure 1B, we specu-
late that the proSP-CI73T species in the EEA1 positive
compartment might be primarily the additional prepro-
tein species accumulating in the I73T mutant. They are
secreted only by the AECII with the I73T mutation and
might be reinternalized as well. On the other hand,
proSP-CWT, but rarely proSP-CI73T, colocalized with
syntaxin 2, a SNARE protein involved in the secretion
of lung surfactant, found in the plasma membrane and
lamellar bodies of AECII (Figure 2B). Interestingly, our
data propose the influence of hydroxychloroquine and
methylprednisolone on localization and routing of
proSP-CWT moving it toward early endosomal vesicles.
On the other hand, methylprednisolone showed the
capacity to partially correct the mislocalization/routing
defect of proSP-CI73T (Figure 5).
The expression of mutated proteins frequently results
in elevated cell stress. This has been shown for the BRI-
CHOS domain SP-C mutations L188Q and Δexon4
[14,15]. We found that the constitutive expression of
SP-CI73T moderately increased cell lethality under nor-
mal growth conditions (Figure 3A), maybe as a result of
the ability of the cellular system to adapt to the pre-
sence of stress, as reported in [39]. The additional exo-
genous stress, imposed in our experiments by exposure
to pharmaceuticals used in ILD therapy, might shift this
balance out of the tolerable range. Treatment of the
cells with azathioprine drug almost doubled the number
of dying I73T mutant cells compared to WT. This
aggravation was much less pronounced in the presence
of methylprednisolone, hydroxychloroquine or
cyclophosphamide.
Intracellular stress is in part handled by endogenous
chaperones. Still without pharmacological boost, such
cytoprotective mechanisms may not always be sufficient
to normalize the cell function and maintain production
of the bioactive surfactant with a normal lipid/protein
composition. We determined the change in expression
of the four important chaperones under the influence of
the same ILD drugs. We found that the influence of
azathioprine on the chaperones was almost the same in
proSP-CWT-and proSP-CI73T-expressing cells, leaving no
protection for additional stress, being a potent stress
factor per se (Figure 4A-D). In contrast, hydroxychloro-
quine treatment led to an 81% increase in HSP90, and
75% increase in calreticulin expression in I73T mutant
cells over WT cells (Table 1), thereby possibly protect-
ing the cells against the additional stress and enhancing
the ER folding capacity. HSP90 seemed to be targeted
by all tested pharmaceuticals, while calnexin levels were
refractory to stimulation (Figure 4). Treatment with the
four drugs did not change the pattern of the proSP-C
processing bands observed in the immunoblots in Figure
1A (data not shown).
The lipid composition of the stable MLE-12 cells was
similar to that previously described in human foetal
AECII, especially with regard to PC composition [40]. In
the SP-CI73T expressing cells we found a pronounced
drop of total cellular PC, whereas LPC was increased
(Figure 6A, additional file 1: supplemental Table S1). It
is known that PC is degraded to LPC by an intrinsic
phospholipase A2-like activity, and that LPC is toxic to
various cells [41]. Increased LPC may therefore be a
result of increased phospholipase activity due to the pre-
sence of mutated SP-C. SP-C dysfunction may also lead
to a diminished activity of acyltransferases which reace-
tylate LPC. LPC is a known inhibitor of the lung
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surfactant activity and has the ability to penetrate
directly into interfacial films to impair lowering of the
alveolar surface tension during dynamic compression
[42,43]. Elevated LPC levels in the SP-CI73T-expressing
cells could also explain the heightened sensitivity
towards exogenous stress described above. Generation
of LPC cannot account for the decrease of PC mass in
SP-CI73T expressing cells, but additional factors, which
directly interfere with the synthesis and packaging of
PC, must also be responsible. This is in line with the
observed grossly altered pattern of the fatty acid species
of the different phospholipid classes, including PC in
SP-CI73T cells (Table 2, additional file 1: supplemental
Table S1).
AECII secrete the surfactant phospholipids into the
alveolar space where it lowers surface tension. Among
phospholipids secreted by the I73T mutants PC was
again decreased by 27% and LPC was increased by 57%,
compatible with a reduced surfactant function [40,43].
Treatment with methylprednisolone or hydroxychloro-
quine ameliorated the increase in intracellular and
secreted LPC and decrease in secreted PC, but did not
completely correct it (Figure 6A, B). The capacity of the
treatment with methylprednisolone and hydroxychloro-
quine to correct the lipid disturbances caused by I73T
mutation (Figure 6B) represent one of the mechanisms
by which these treatments are empirically helpful in
some patients with I73T mutations (own unpublished
results, [19]).
Lastly, the index patient with the I73T mutation in
our previous study displayed a mild interstitial chronic
inflammation and most of the infiltrated leukocytes
were CD3+ and CD4+ T-lymphocytes [17]. We found
that cells with the I73T mutation released soluble fac-
tors into the medium that increase surface expression of
CCR2 and CXCR1 on CD4+ lymphocytes and CXCR1
on neutrophiles (Figure 7A-C). When activated, the high
affinity IL-8 receptor CXCR1 mediates antibacterial kill-
ing capacity [36,44]. Increases in surface expression
levels of CCR2 and CXCR1, respectively, might have the
potential to modulate the pulmonary immune response
with regard to antibacterial (CXCR1) and profibrotic
(CCR2) responses [36,45]. However, the soluble factors
involved in the induction of chemokine receptor expres-
sion as well as the functional consequences of this phe-
nomenon remain to be addressed in future studies.
Conclusions
We showed impaired proSP-C processing, altered cellu-
lar stress tolerance and unfavorable changes of the sur-
factant lipid composition in a murine AECII model cell
line. Some of the demonstrated cellular aspects behind
the disease could be modulated with drugs used in the
therapy of ILD patients, thereby giving insight into their
potential therapeutic mechanism on a cellular level. We
also demonstrated that AECII with I73T mutation could
signal to the surrounding cells of the immune system
through secretion of soluble factors. Therefore, our
study adds to understanding of the effects that SFTPC
mutations impose on (pro)SP-C and AECII cell biology
and pave the way for a more precise pharmacological
targeting in patients with SP-C deficiency.
Methods
Plasmid vectors
Eukaryotic expression vectors containing the full human
SFTPC gene fused to either EGFP-tag (pEGFP-N1/hSP-
C1-197 and pEGFP-C1/hSP-C1-197 to obtain proSP-C with
EGFP fused to the C- or N-terminus respectively) or
hemagglutinin (HA)-tag (proSP-C with N-terminal HA-
tag) were obtained as previously described [12]. I73T
point mutation was introduced into the wild-type (WT)
SFTPC gene in these vectors using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, USA) and
the following primers: I73T_forward: 5’-GGT TCT GGA
GAT GAG CAC TGG GGC GC-3’, I73T_reverse:
5’-GCG CCC CAG TGC TCA TCT CCA GAA CC-3’,
following the recommended protocol. The successful
mutagenesis was confirmed by DNA sequencing.
MLE-12 cell lines and transfection
The mouse MLE-12 lung epithelial cell line (CRL-2119)
[38] was obtained from the American Type Culture Col-
lection (ATCC) and maintained in RPMI medium sup-
plemented with 10% FBS. Cells were transfected using
FuGene 6 (Roche, Penzberg, Germany) according to the
manufacturer’s protocol. Stable transfection of MLE-12
cells with pcDNA3/HA-hSP-C1-197 and pcDNA3/HA-
hSP-CI73T vectors was obtained by selecting transfected
cells in the presence of 600 μg/ml G418 in RPMI med-
ium for four weeks. For drug exposure experiments
stable cells were grown 24 hours in the presence of 10
μM of cyclophosphamide, azathioprine, methylpredniso-
lone or hydroxychloroquine.
Immunoblotting
Total cell proteins were obtained by lysing the cells in
lysis buffer (PBS, 20 mM EDTA, 1% v/v Elugent (Cal-
biochem, Bad Soden, Germany), protease inhibitor
(Complete; Roche, Manheim, Germany). For immuno-
blotting 30 μg protein were separated under reducing
conditions using 10% NuPage Bis-Tris (Invitrogen,
Karlsruhe, Germany) and transferred to a PVDF mem-
brane. The following primary antibodies were used:
monoclonal rat anti-HA-tag (1:1000; Roche), monoclo-
nal mouse anti-GFP (1:500; Clontech, Heidelberg, Ger-
many) and polyclonal goat anti-calnexin (1:500),
polyclonal goat anti-calreticulin (1:500), monoclonal
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mouse anti-HSP90a/b, polyclonal goat anti-HSP70
(1:1000) and monoclonal anti-b-actin HRP conjugate
(1:10000) (all from Santa Cruz Biotechnology, Santa
Cruz, CA). Signal was detected using chemiluminiscent
labeling with Amersham ECL Detection Reagents (GE
Healthcare), densitometrically quantified and normalized
to the b-actin signal.
Immunofluorescence
24 hours after transfection cells grown on coverslips were
fixed with 4% paraformaldehyde, permeabilised with 10%
Triton X-100, blocked 30 min in PBS with 5% FBS. The
following primary antibodies were used and all in 1:200
dilution: polyclonal rabbit anti-mouse LAMP3 (Santa
Cruz), monoclonal mouse anti-human CD63/LAMP3
(Chemicon, Schwalbach, Germany), polyclonal rabbit
anti-EEA1 (Acris Antibodies, Herford, Germany), mono-
clonal mouse anti-ubiquitin (Biomol, Hamburg, Ger-
many) and polyclonal rabbit anti-syntaxin 2 (Synaptic
Systems, Berlin, Germany). Species specific Alexa Fluor
488 or Alexa Fluor 555 secondary antibodies (Invitrogen)
were used at 1:200. Samples were mounted and Alexa
Fluor or GFP fluorescence was examined with Axiovert
135 fluorescent microscope and evaluated with AxioVi-
sion 4.7.1 software (Carl Zeiss, Jena, Germany). For semi-
quantitative assessment of colocalization, high magnifica-
tion confocal microscope images were used. On 14 to 27
different coverslips at least 100 vesicles stained for SP-C
and/or syntaxin 2 were counted in a blinded fashion and
the percentage of vesicles showing staining for both mar-
kers was calculated. Similarly, the percentage of vesicles
stained for SP-C and EEA-1 was calculated.
Lactate dehydrogenase (LDH) assay
LDH activity in cell lysates and culture supernatants was
determined by the method of Decker and Lohmann-
Matthes [46]. Briefly, 100 μl of samples were mixed with
30 μl dye solution (18 mg/ml L-lactate, 1 mg/ml iodoni-
trotetrazolium in PBS). After adding 15 μl of the catalyst
(3 mg/ml NAD+, 2.3 mg/ml diaphorase, 0.03% BSA,
1.2% sucrose in PBS), absorbance at 492 nm was deter-
mined at one minute intervals for 15 minutes at 37°C.
Absolute LDH activity was calculated from a standard
curve, using purified LDH (Sigma, Munich, Germany).
The lower limit of detection was 20 Units/L; the assay
was linear to 2500 Units/L.
Mass spectrometric lipid analysis
For lipid analysis cells grown in Petri dishes were har-
vested by scraping off in 2 mL PBS supplemented with
protease inhibitor (Complete, Roche). The cell suspen-
sion was sonicated (four strokes, 10 seconds; Branson
Digital Sonifier S450D). Lipid classes and subspecies
were determined by electrospray ionization tandem mass
spectrometry (ESI-MS/MS) using direct flow injection
analysis, as described previously [47,48]. Cells were
extracted according to the Bligh and Dyer method in the
presence of non-naturally occurring lipid species used as
internal standards [49]. A precursor ion scan of m/z 184
specific for phosphocholine containing lipids was used
for phosphatidylcholine (PC), sphingomyelin (SPM) [48]
and lysophosphatidylcholine (LPC) [47]. Neutral loss
scans of m/z 141 and m/z 185 were used for phosphati-
dylethanolamine (PE) and phosphatidylserine (PS),
respectively [50]. Phosphatidylglycerol (PG) was analyzed
using a neutral loss scan of m/z 189 of ammonium
adduct ions [51]. Ceramide and glucosylceramide were
analyzed as previously described [52] using N-heptadeca-
noyl-sphingosine as internal standard. Quantification was
achieved by calibration lines generated by addition of
naturally occurring lipid species to pooled cell homoge-
nate. All lipid classes were quantified with internal stan-
dards belonging to the same lipid class, except SM (PC
internal standards). Each lipid class was calibrated with a
variety of species covering chain lengths and number of
double bonds of naturally occurring species. Correction
of isotopic overlap of lipid species and data analysis was
performed by self-programmed Excel macros for all lipid
classes according to the described principles [48].
Flow cytometry
Human lymphocytes and neutrophils were isolated from
whole blood using LeucoSep (Greiner Bio-One, Solin-
gen-Wald, Germany) and Ficoll-Isopaque gradient den-
sity isolation method (GE Healthcare) according to the
manufacturer’s instructions. Cells were incubated for 6
hours (neutrophils) or 24 hours (lymphocytes) at 37°C
with supernatants of MLE-12 cells expressing wild-type
or mutant proSP-C. Cell-free supernatants were col-
lected after 48 hours of growth and concentrated 7-fold,
using Microsep 1 k centrifugal concentrators (Millipore,
Schwalbach, Germany). Cells were analyzed by four-col-
our flow cytometry (FACSCalibur; BD Pharmingen, Hei-
delberg, Germany) as described previously [35]. The
following antibodies were used: PE-conjugated mouse
anti-human CCR2-B (R&D Systems, Minneapolis, USA),
FITC labeled anti-human CD8, FITC labeled anti-
human CD4, PE-conjugated mouse anti-human CD11b/
Mac-1, PE-conjugated mouse anti-human CD181
(CXCR1, IL-8RA) (all BD Pharmingen). Results are pre-
sented as mean fluorescence intensity (MFI) after sub-
tracting background binding provided by non-specific
isotypes. Calculations were performed with CellQuest
analysis software (BD Pharmingen).
Statistical methods
Since the data was distributed non-Gaussian, non-para-
metric tests were used for comparison of two unpaired
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groups (Mann Whitney test). The results are given as
means ± standard error (SE) of the individual number of
different subjects, each individual value representing the
mean of 3-4 determinations or as indicated. For lipid analy-
sis the results are presented as means with standard devia-
tion and comparisons were made by ANOVA followed by
Tukey’s post hoc multi comparisons test. For correlations,
Spearman’s non-parametric test was used. P-values of less
than 0.05 were considered statistically significant.
Additional material
Additional file 1: Table S1. Phospholipid classes and molecular
species profile of transfected MLE-12 cells stably expressing SFTPC
I73T mutation. Data are means and standard deviation of three
independent experiments, each performed in duplicate. The mutant
(I73T) and wild type (WT) were compared by ANOVA followed by Tukeys
multiple comparison test. P-values are shown.
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